Castelli Jeff's Form 4 filing
Amicus Therapeutics, Inc.FOLD · filed Dec 20, 2023
- Accession no.
- 0000950170-23-071911
- Filed
- Dec 20, 2023
- Trade date
- Dec 18-20, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $253.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Castelli JeffCIK 0001569225 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 18, 2023 | Common Stock | AGrant or awardAcquired | +8,643 | $0.00F1 | $0 | 377,236 | Direct | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −17,500 | $13.25 | −$231,875 | 359,736 | Direct | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −1,654 | $13.10 | −$21,667.4 | 358,082 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a contingent right to receive common stock in the amount shown, for no consideration, due to the satisfaction of performance criteria underlying an award of performance based restricted stock units granted in 2021. Such units remain outstanding on the date hereof and will fully vest on December 31, 2023, subject to the Reporting Person's continued service with the Company.
Referenced by the price of 1 transaction in Table I.
Remarks
All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2023.